Profound Medical Corp. — Form 8-K
Filed October 7, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Profound Medical reported preliminary unaudited Q3 2026 revenue of $9.8–$10.0 million, representing 85–89% year-over-year growth from $5.3 million in Q3 2025 and 292–300% sequential growth from $2.5 million in Q2 2026. This exceeds Bloomberg analyst consensus of $6.78 million by 45–47% and reflects gross margin exceeding 70%, driven by increased commercial activity across installed base and new customer accounts.
Why this rating
Strong beat and accelerating growth material to $152M market-cap company; Q3 revenue ~6.5–7% of annual run-rate implies trajectory shift, but preliminary and subject to revision. Execution validation vs consensus highly positive.
Price action (we called it positive)
before filing · preread $6.77 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 7, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.